Today AKER ranks # as BUY CANDIDATE.
Today AKER ranks # as BUY CANDIDATE.

AKER stock Akers Biosciences Inc

AKER stock
Akers Biosciences Inc

18 January 2019
Change 2.21%
Chart period: 2018-10-19 - 2019-01-18




Request Prediction

Akers Biosciences Inc Stock Analysis

Technical stock analysis for 18 January 2019

Buy candidate since 2019-01-18
Shorts n/a
Cash n/a
Loans n/a
Beta -0.65
ROA -123.03

Akers Biosciences Inc gained 2.21% in the last trading day, rising from $1.36 to $1.39 The price has been going up and down for this period, and there has been a 16.81% gain for the last 2 weeks. Volume fell in the last day by -106 338 shares, and in total, 197 771 shares bought and sold for approximately $274 902.00. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.

Close price at the end of the last trading day (Friday, 18th Jan 2019) of the AKER stock was $1.39. This is 2.21% more than the trading day before Thursday, 17th Jan 2019.

During day the stock fluctuated 6.06% from a day low at $1.32 to a day high of $1.40.

30 day high of the AKER stock price was $1.54 and low was $0.57.
90 day high was $3.20 and low was $0.29.
52 week high for the Akers Biosciences Inc - $3.20 and low - $0.20.


Akers Biosciences Inc lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 20.48% during the next 3 months and, with 90% probability hold a price between $0.85 and $3.55 at the end of this period.

Click here for today's Top 5 Trending Companies


Akers Biosciences Inc holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $1.37 and $1.21. A break down below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Wednesday January 16, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 56 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

On the downside, the stock finds support just below today's level from accumulated volume at $1.27 and $1.23.

There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Akers Biosciences Inc finds support just below today's level at $1.27. If this is broken, then the next support from accumulated volume will be at $1.23 and $1.13.

Support: $1.27 Price: $1.39 Resistance: $1.60


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.08 between high and low, or 6.06%. For the last week the stock has had a daily average volatility of 9.64%.

Our recommended stoploss: $1.28 (-8.19%) (This stock has very high daily movements and this gives very high risk. There is a sell signal from pivot top found 2 days ago.)

Overall risk:

Very Low Low Medium High Very High


Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Hold/Accumulate to a Buy Candidate.

Today AKER ranks # as BUY CANDIDATE.
Today AKER ranks # as BUY CANDIDATE.